Recent yellow fever outbreaks in multiple countries in Africa and South America have necessitated the use of mass vaccination campaigns to prevent further spread. Consequently, global stockpiles of the yellow fever vaccine have been depleted. With funding from CDC, IDI is conducting a study to evaluate the immune responses when a reduced dose of the yellow fever vaccine is administered to children aged between 9 and 23 months.